NCT01538225View on ClinicalTrials.gov

Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Multiple Sclerosis
Interventions
DRUG

Sativex®

"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"

DRUG

Placebo

"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"

Trial Locations (1)

20132

Institute of Experimental Neurology, Milan

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY

NCT01538225 - Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity | Biotech Hunter | Biotech Hunter